Clovis Oncology Inc (NDAQ:CLVS) Rating Reconfirmed by Credit Suisse Group Today

June 19, 2017 - By Hazel Jackson

 Clovis Oncology Inc (NDAQ:CLVS) Rating Reconfirmed by Credit Suisse Group Today

Investors sentiment decreased to 1.03 in Q4 2016. Its down 0.97, from 2 in 2016Q3. It worsened, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. 38 funds opened positions while 42 raised stakes. 35.69 million shares or 2.51% less from 36.61 million shares in 2016Q3 were reported.

Sei Investments holds 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 7,400 shares. Palo Alto Invsts Limited Liability owns 3.80 million shares for 9.64% of their portfolio. Td Asset Management Inc has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Alliancebernstein Lp reported 46,040 shares. Css Ltd Liability Company Il has invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). Jasper Ridge Prns Ltd Partnership stated it has 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Fincl Bank Of America Corporation De stated it has 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Ubs Asset Mgmt Americas Incorporated stated it has 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Art Advisors Limited Liability Company holds 0.2% or 75,700 shares. Alpine Woods Capital Invsts Lc stated it has 6,000 shares or 0.01% of all its holdings. Tiaa Cref Investment Management Ltd Liability reported 273,070 shares. Voya Inv Mngmt Ltd Co stated it has 12,469 shares or 0% of all its holdings. Franklin Resource has 0.01% invested in Clovis Oncology Inc (NASDAQ:CLVS). Meeder Asset Mngmt Inc owns 214 shares. Blackrock Inv Mngmt invested in 118,871 shares.

Since March 15, 2017, it had 0 insider buys, and 3 insider sales for $528,600 activity. IVERS-READ GILLIAN C sold $200,970 worth of stock or 3,000 shares.

Clovis Oncology Inc (NDAQ:CLVS) Rating Reaffirmed

Clovis Oncology Inc (NDAQ:CLVS) shares have had their Outperform Rating reaffirmed by analysts at Credit Suisse Group in a report revealed on Friday, 16 June.

Investors sentiment decreased to 1.03 in Q4 2016. Its down 0.97, from 2 in 2016Q3. It worsened, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. 38 funds opened positions while 42 raised stakes. 35.69 million shares or 2.51% less from 36.61 million shares in 2016Q3 were reported.

Sei Investments holds 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 7,400 shares. Palo Alto Invsts Limited Liability owns 3.80 million shares for 9.64% of their portfolio. Td Asset Management Inc has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Alliancebernstein Lp reported 46,040 shares. Css Ltd Liability Company Il has invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). Jasper Ridge Prns Ltd Partnership stated it has 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Fincl Bank Of America Corporation De stated it has 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Ubs Asset Mgmt Americas Incorporated stated it has 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Art Advisors Limited Liability Company holds 0.2% or 75,700 shares. Alpine Woods Capital Invsts Lc stated it has 6,000 shares or 0.01% of all its holdings. Tiaa Cref Investment Management Ltd Liability reported 273,070 shares. Voya Inv Mngmt Ltd Co stated it has 12,469 shares or 0% of all its holdings. Franklin Resource has 0.01% invested in Clovis Oncology Inc (NASDAQ:CLVS). Meeder Asset Mngmt Inc owns 214 shares. Blackrock Inv Mngmt invested in 118,871 shares.

Since March 15, 2017, it had 0 insider buys, and 3 insider sales for $528,600 activity. IVERS-READ GILLIAN C sold $200,970 worth of stock or 3,000 shares.

About 6.98 million shares traded or 347.44% up from the average. Clovis Oncology Inc (NDAQ:CLVS) has risen 282.71% since June 19, 2016 and is uptrending. It has outperformed by 266.01% the S&P500.

Investors wait Clovis Oncology Inc (NASDAQ:CLVS) to report on August, 14. its quarterly earnings Wall Street analysts expect $-1.37 earnings per share, up $0.70 or 33.82 % from last year’s $-2.07 same quarter earnings. Clovis Oncology Inc’s Wall Street analysts see 3.01 % negative EPS growth, taking into account the $-1.33 EPS reproted in the previous quarter,

Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has market cap of $3.97 billion. The Company’s product candidates include Rociletinib, Rubraca and Lucitanib. It currently has negative earnings. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

More notable recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Globenewswire.com which released: “Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of …” on June 14, 2017, also Benzinga.com with their article: “Clovis Oncology’s 45% Pre-Market Surge, Explained” published on June 19, 2017, Nasdaq.com published: “Commit To Purchase Clovis Oncology At $40, Earn 24.8% Annualized Using Options” on May 26, 2017. More interesting news about Clovis Oncology Inc (NASDAQ:CLVS) were released by: Marketwatch.com and their article: “Clovis Oncology stock surges 50% on positive late-stage cancer trial results” published on June 19, 2017 as well as Businesswire.com‘s news article titled: “Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting” with publication date: May 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.